Baricitinib Therapeutic Cheat Sheet
Baricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l …
Baricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l … 
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o … 
The skin smoothie is one of the latest skincare trends popularized on TikTok. Made famous by TikTok creator Amy K, skin smoothies involve mixing several skincare products and applying the mixture to the skin at the same time. The most popular combination on TikTok involves mixing petroleum jelly, moisturizing lotion, serum and self-tanning lotion. Users claim applying the products together leads t … 
Which of the following treatments for the shown rash with 15% body surface area (BSA) involvement is least likely to be associated with an infection?
A. Methotrexate
B. Cyclosporine
C. Adalimumab
D. Infliximab
E. Acitretin
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Han shares why it’s an exciting time to treat psoriasis, and why the developments of the past year have bolstered the clinician’s armamentarium. Watch and lear … 